[Anti-metabolic syndrome effects of candesartan].
Yamauchi
Toshimasa
T
Department of Metabolic Diseases, Graduate School of Medicine, The University of Tokyo.
Kadowaki
Takashi
T
D052242:Adiponectin / Q000502:physiology; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000818:Animals; D001562:Benzimidazoles / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D003924:Diabetes Mellitus, Type 2 / Q000517:prevention & control; D024821:Metabolic Syndrome / Q000517:prevention & control*; D051379:Mice; D009765:Obesity / Q000503:physiopathology; D047492:Peroxisome Proliferator-Activated Receptors / Q000502:physiology; D013777:Tetrazoles / Q000627:therapeutic use*
D052242:Adiponectin; D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D047492:Peroxisome Proliferator-Activated Receptors; D013777:Tetrazoles; C081643:candesartan